POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer - European Medical Journal

POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer

Oncology
At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now